News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports Full-Year 2013 Financial Results


2/25/2014 7:27:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today its full-year 2013 financial results, a $100M debt facility and ongoing progress with IPI-145, the Company’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

“Throughout 2013, Infinity made significant progress with IPI-145, demonstrating broad activity and tolerability across multiple hematologic malignancies,” commented Adelene Q. Perkins, Infinity’s chair and chief executive officer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES